Venomtech are very excited and honoured to announce the formation of the Board of Directors combining decades of pharmaceutical, clinical and financial experience. Our founding board members represent a group of leaders who are strong advocates for the mission of the organisation. Bringing a wide range of experience and talents, the board is in the perfect position to lead Venomtech into the future of biotherapeutics. The founding members include:
Managing Director – Steven Trim. Founder of Venomtech Ltd. After 10 years in the pharmaceutical industry as a molecular biologist and safety delegate followed by a brief research associate position in a comparative genomics lab, Venomtech was established to meet the need for venom reagents in the UK. Venomtech now produce hit-to-tool, automation compatible biological libraries targeted to therapeutic areas to maximise hit potential.
Chairman – Dr Denis Henrard. With over 24 years’ experience as an international pharmaceutical business developer, Denis has made a significant impact in developing Venomtech’s research strategy to develop an intellectual property portfolio.
Financial Director – Clive Newell. Founder and Principal Director of Halagen Ltd (established in 2005) – a company providing experienced Finance Directors for businesses on a part-time basis. Halagen specialise in working with ambitious, high-growth SMEs who want assistance in making critical decisions for the development of their companies.
Scientific Advisor & Non Executive Director – Professor Karol Sikora. A world respected oncologist and campaigner for better universal cancer treatment. Internationally famous for his research into the behaviour of cancer cells and the use of gene therapy as treatment.